NBIX Neurocrine Biosciences, Inc. - Common Stock

NASDAQ · Biotechnology · 在 SEC EDGAR 上查看 ↗
$155.47
价格 · 八月 19, 2026
截至...的财报数据 七月 31, 2026
52周区间
$123–$186
51% of range
分析师评级
BUY
36 analysts
目标价
$212
+36% upside
P/E (TTM)
33.3
ROE
16.1%
净利润率
16.7%

关于 Neurocrine Biosciences, Inc. - Common Stock 公司概况（来自维基百科）

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

阅读更多

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.

History

Neurocrine was founded in San Diego, California, in 1992. The company's academic founders were Wylie Vale of the Salk Institute for Biological Studies, and Lawrence Steinman of Stanford University. The company was backed and organized by Larry Bock of Avalon Ventures among others.

In 1995, the company collaborated with Belgium-based Janssen Pharmaceutica N.V. to develop treatments for psychiatric disorders utilizing corticotropin releasing factor (CRF) antagonists, a class of compounds to treat psychiatric, neurological and gastrointestinal diseases including anxiety, depression and irritable bowel syndrome. The company underwent an IPO in May 1996, listing on the NASDAQ exchange under the symbol NBIX and raising $34.2 million.

In October 1996, Eli Lilly and Company agreed to pay Neurocrine $74 million over five years to develop drugs for obesity and Alzheimer's disease based on its research of CRF-binding protein-ligand inhibitors.

In July 2001, Neurocrine and GlaxoSmithKline entered into a worldwide research, development and commercialization agreement, including a collaborative research program for up to five years to identify and develop CRF-R antagonist compounds. The collaboration also included worldwide development and commercialization of NBI-34041 as well as potential backup candidates resulting from the research program. Neurocrine received upfront fees and early milestone payments totaling $25.5 million.

In December 2002, Neurocrine reached an agreement with Pfizer for the rights to its experimental insomnia drug, indiplon. The deal paid Neurocrine $100 million initially with a possible $300 million more if the drug met regulatory and sales goals. In May 2006, the FDA issued a non-approvable letter for a modified-release 15 mg formulation of indiplon and an approvable letter with stipulations for 5 mg and 10 mg immediate-release formulations. As a result, Pfizer terminated its agreement with Neurocrine. Following a resubmission of the 5 mg and 10 mg formulations in December 2007, Neurocrine's new drug application was deemed 'approvable' but the FDA requested additional studies. The company discontinued development of the drug in the United States. In 2007, Neurocrine partnered with Dainippon Sumitomo Pharma to develop and commercialize indiplon in Japan. The deal paid Neurocrine $20 million up front with the ability to receive milestone payments and royalties based on the commercialization of indiplon in Japan.

Kevin Gorman replaced Gary Lyons as CEO of the company in January 2008. Lyons was CEO and president of the company since its founding and maintained a role on the company's board of directors.

On June 16, 2010, Neurocrine agreed to a deal with AbbVie Inc. (previously Abbott Laboratories) worth up to $575 million with Neurocrine granting AbbVie the worldwide rights to develop and commercialize elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist to treat endometriosis and uterine fibroids. The deal paid Neurocrine $75 million up front.

In April 2017, the FDA approved valbenazine for the treatment of TD. At the time of approval, it was the first and only drug approved for adults with TD. Neurocrine is also studying valbenazine in clinical trials for the treatment of Tourette Syndrome. In October 2017, Neurocrine announced that it had been granted orphan drug designation status from the FDA for valbenazine for the treatment of pediatric patients with Tourette syndrome.

In February 2017, Neurocrine announced an exclusive licensing agreement for the development and commercialization of the Parkinson's disease drug, opicapone, in North America with the Portugal-based pharmaceutical company Bial. As part of the agreement, Neurocrine provided an upfront payment of $30 million and agreed to fund development activities for FDA approval in the United States. Bial is eligible to receive additional milestone payments of up to $115 million and a percentage of net sales.

In September 2017, AbbVie submitted a NDA to the FDA for elagolix for the management of endometriosis and associated pain. The submission was supported by two similar Phase 3 clinical studies involving 1,700 women. In October 2017, AbbVie and Neurocrine announced that the FDA granted priority review for the elagolix NDA. A final regulatory decision on the drug will come during the third quarter of 2018. The companies are also developing elagolix for the treatment of uterine fibroids which is in Phase III development.

In 2021,Nexera Pharmain Japan licensed out its investigational schizophrenia drug, NBI-1117568, to Neurocrine Biosciences for development.

In August 2024, Neurocrine announced the results of a Phase II clinical trial of NBI-1117568 . The drug demonstrated a 7.5-point improvement in the Positive and Negative Syndrome Scale (PANSS), which was lower than the 8.4-point improvement seen with KarXT (developed by Karuna Therapeutics) and the 12.7-point improvement seen with Emraclidine (developed by Cerevel Therapeutics), both of which were also in clinical trials at the time. Additionally, the study found no dose-dependent response to NBI-1117568. As a result, Neurocrine's stock price fell 19% the following day as investors were disappointed by the results.

Product pipeline

Elagolix – gonadotropin-releasing hormone receptor antagonist undergoing FDA review for the treatment of endometriosis and in clinical trials for uterine fibroids

Opicapone – A once daily catechol-O-methyl transferase inhibitor in trials for Parkinson's disease

NBI-74788 – Corticotropin-releasing factor (CRF) receptor antagonist

NBI-1117568 - A drug that stimulates muscarinic receptors and is used to treat schizophrenia.

来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗

Wikidata ↗

NBIX 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围

价格
$155.47
市值
$15.56B
P/E (TTM)
33.3
每股收益 (TTM)
$4.67
营收 (TTM)
$2.86B
股息收益率
—
ROE
16.1%
负债/权益
—
52周区间
$123 – $186

NBIX 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图

10年表现 收入、净利润、利润率和每股收益趋势

营收与净利润 $2.86B
10-point trend, +18970.0%
2016-12-31 → 2025-12-31
EPS $4.67
10-point trend, +386.5%
2016-12-31 → 2025-12-31
自由现金流 $749M
10-point trend, +778.9%
2016-12-31 → 2025-12-31
利润率 16.7%

估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？

指标
5年趋势
NBIX
同行中位数
P/E (TTM)
5-point trend, -67.2%
33.3
16.9
P/S (TTM) (市销率 (TTM))
5-point trend, -30.4%
5.4
9.6
P/B (市净率)
5-point trend, -25.8%
4.8
7.7
Price / FCF (股价/自由现金流)
5-point trend, -45.3%
20.8
—

盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)

指标
5年趋势
NBIX
同行中位数
Operating Margin (营业利润率)
5-point trend, +139.4%
21.6%
—
Net Profit Margin (净利润率)
5-point trend, +111.8%
16.7%
-36.9%
ROA
5-point trend, +143.3%
11.5%
-21.8%
ROE
5-point trend, +144.2%
16.1%
-47.3%
ROIC
5-point trend, +95.9%
12.9%
—

财务健康 债务、流动性、偿付能力 — 资产负债表强度

指标
5年趋势
NBIX
同行中位数
Current Ratio (流动比率)
5-point trend, -14.3%
3.4
3.5
Quick Ratio (速动比率)
5-point trend, -48.4%
1.9
—

成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)

指标
5年趋势
NBIX
同行中位数
Revenue YoY (营收同比增长)
5-point trend, +152.4%
21.4%
—
Revenue CAGR 3Y (营收3年复合年增长率)
5-point trend, +152.4%
24.3%
—
Revenue CAGR 5Y (营收5年复合年增长率)
5-point trend, +152.4%
22.3%
—
EPS YoY
5-point trend, +407.6%
41.9%
—
Net Income YoY (净利润同比增长)
5-point trend, +434.2%
40.2%
—

每股指标 每股收益 (EPS)、每股净资产、每股现金流、每股股息

指标
5年趋势
NBIX
同行中位数
EPS (Diluted) (EPS (稀释))
5-point trend, +407.6%
$4.67
—

资本效率 资产周转率、库存周转率、应收账款周转率

指标
5年趋势
NBIX
同行中位数

NBIX 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间

买入 36 位分析师
  • 强烈买入 14 38.9%
  • 买入 17 47.2%
  • 持有 5 13.9%
  • 卖出 0 0.0%
  • 强烈卖出 0 0.0%

12个月价格目标

27 位分析师 · 2026-08-15
中位数目标 $215.00 +38.3%
平均目标 $211.57 +36.1%

收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期

平均惊喜
0.24%
期间 EPS Actual EPS 预期 惊喜
2026年6月30日 $1.39 $1.37 0.02%
2026年3月31日 $1.91 $1.20 0.71%
2025年12月31日 $1.91 $1.20 0.71%
2025年9月30日 $2.04 $1.62 0.42%
2025年6月30日 $1.06 $0.99 0.07%
2025年3月31日 $0.08 $0.56 -0.48%

同行比较（GICS 子行业） 关键指标与行业同行对比

股票代码 市值 P/E 营收同比增长 净利润率 ROE 毛利率
NBIX $14.20B 30.4 21.4% 16.7% 16.1% —
INCY $19.60B 15.4 21.2% 25.0% 27.6% —
MRNA $11.62B -4.1 -39.9% -145.2% -31.3% —
UTHR $21.27B 17.5 10.6% 41.9% 18.7% 87.9%
BBIO $14.90B -20.2 126.3% -146.0% 41.2% —
BMRN $11.43B 33.0 12.9% 10.8% 5.8% —
EXEL $11.44B 15.7 7.0% 33.7% 37.3% —
ARWR $4.68B -3449.0 23258.2% -0.20% -0.50% —
MDGL $13.30B -45.3 432.1% -30.1% -44.4% —
HALO $7.93B 26.3 37.5% 22.7% 166.1% —

完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表

损益表 17
NBIX 的年度损益表数据
指标 趋势 202520242023202220212020201920182017201620152014
Revenue 12-point trend, +2860500000.00 $2.86B $2.36B $1.89B $1.49B $1.13B $1.05B $788M $451M $162M $15M $20M $0
Cost of Revenue 10-point trend, +52100000.00 $52M $34M $40M $23M $14M $10M · $5M $1M $0 $0 ·
R&D Expense 5-point trend, +245.8% · · · · · · · $161M $122M $94M $81M $46M
SG&A Expense 12-point trend, +6328.3% $1.16B $1.01B $888M $753M $583M $433M $354M $249M $170M $68M $32M $18M
Operating Expenses 12-point trend, +3379.8% $2.24B $1.78B $1.64B $1.24B $1.03B $883M $716M $414M $293M $162M $114M $64M
Operating Income 12-point trend, +1061.2% $619M $570M $251M $249M $102M $163M $72M $37M $-131M $-147M $-94M $-64M
Interest Expense 9-point trend, +4600000.00 · · $5M $7M $26M $33M $32M $30M $20M $0 $0 ·
Interest Income 3-point trend, +351.2% · · · · · · · · · $3M $2M $629.0K
Other Non-op 12-point trend, +479344.4% $86M $-84M $81M $-35M $-1M $-56M $-26M $-15M $-11M $6M $20.0K $18.0K
Pretax Income 10-point trend, +600.0% $705M $486M $332M $214M $101M $107M $46M $22M $-143M $-141M · ·
Income Tax 12-point trend, +226800000.00 $227M $145M $82M $59M $12M $-301M $10M $700.0K $0 $0 $0 $0
Net Income 12-point trend, +890.5% $479M $341M $250M $154M $90M $407M $37M $21M $-143M $-141M $-89M $-61M
EPS (Basic) 12-point trend, +693.8% $4.81 $3.40 $2.56 $1.61 $0.95 $4.38 $0.40 $0.23 $-1.62 $-1.63 $-1.05 $-0.81
EPS (Diluted) 12-point trend, +676.5% $4.67 $3.29 $2.47 $1.56 $0.92 $4.16 $0.39 $0.22 $-1.62 $-1.63 $-1.05 $-0.81
Shares (Basic) 12-point trend, +33.4% 99,500,000 100,400,000 97,700,000 95,800,000 94,600,000 93,100,000 91,600,000 90,200,000 88,089,000 86,713,000 84,496,000 74,577,000
Shares (Diluted) 12-point trend, +37.4% 102,500,000 103,700,000 101,000,000 98,900,000 97,900,000 97,800,000 95,700,000 95,400,000 88,089,000 86,713,000 84,496,000 74,577,000
EBITDA 11-point trend, +1061.2% $619M $570M $251M $249M $102M $163M $72M $37M $-131M $-147M · $-64M
资产负债表 28
NBIX 的年度资产负债表数据
指标 趋势 202520242023202220212020201920182017201620152014
Cash & Equivalents 12-point trend, +2199.0% $713M $233M $251M $263M $341M $187M $112M $142M $255M $83M $74M $31M
Short-term Investments 8-point trend, +127.6% · · · · $370M $614M $558M $509M $261M $224M $305M $163M
Receivables 10-point trend, +686800000.00 $687M $479M $439M $350M $186M $157M $127M $57M $31M $0 · ·
Inventory 10-point trend, +69000000.00 $69M $57M $38M $35M $30M $28M $17M $11M $1M $0 · ·
Prepaid Expense 2-point trend, +252.0% $171M $48M · · · · · · · · · ·
Other Current Assets 12-point trend, +2535.4% $116M $64M $98M $79M $46M $30M $17M $19M $7M $3M $5M $4M
Current Assets 12-point trend, +1172.8% $2.52B $1.72B $1.61B $1.45B $973M $1.02B $831M $738M $555M $310M $384M $198M
PP&E (Net) 12-point trend, +3482.0% $90M $83M $71M $59M $59M $45M $42M $34M $11M $6M $3M $3M
PP&E (Gross) 12-point trend, +565.9% $208M $189M $154M $125M $110M $86M $76M $62M $38M $32M $30M $31M
Accum. Depreciation 12-point trend, +311.5% $118M $106M $83M $66M $52M $42M $34M $28M $28M $26M $27M $29M
Goodwill 5-point trend, +6100000.00 $6M $6M $6M $5M $0 · · · · · · ·
Intangibles 5-point trend, +4700000.00 $5M $36M $36M $37M $0 · · · · · · ·
Other Non-current Assets 7-point trend, +48700000.00 $49M $52M $50M $25M $4M $6M $0 · · · · ·
Total Assets 12-point trend, +1805.7% $4.63B $3.72B $3.25B $2.37B $2.07B $1.73B $1.31B $993M $818M $365M $475M $243M
Accounts Payable 12-point trend, +274005.7% $674M $462M $449M $348M $226M $169M $141M $86M $6M $5M $3M $246.0K
Accrued Liabilities 3-point trend, +83.3% · · · · · · · · · $21M $19M $12M
Current Liabilities 12-point trend, +4645.9% $743M $508M $655M $538M $246M $186M $565M $88M $54M $30M $26M $16M
Capital Leases 8-point trend, +415300000.00 $415M $455M $258M $94M $105M $94M $87M $0 · · · ·
Deferred Tax $0 · · · · · · · · · · ·
Other Non-current Liabilities 12-point trend, +84400.0% $220M $166M $106M $30M $12M $10M $17M $36M $0 $113.0K $221.0K $260.0K
Total Liabilities 12-point trend, +3914.7% $1.38B $1.13B $1.02B $661M $698M $608M $669M $512M $445M $50M $50M $34M
Common Stock 12-point trend, +31.6% $100.0K $100.0K $100.0K $100.0K $100.0K $100.0K $100.0K $91.0K $89.0K $87.0K $86.0K $76.0K
Paid-in Capital · · · · · · · · · · · $1.04B
Retained Earnings 12-point trend, +154.2% $448M $29M $-157M $-407M $-636M $-725M $-1.13B $-1.18B $-1.20B $-1.06B $-915M $-826M
AOCI 12-point trend, +4829.2% $13M $6M $7M $-8M $-2M $2M $1M $-2M $-2M $-318.0K $-977.0K $-277.0K
Stockholders' Equity 12-point trend, +1458.8% $3.25B $2.59B $2.23B $1.71B $1.37B $1.13B $637M $481M $372M $315M $424M $209M
Liabilities + Equity 12-point trend, +1805.7% $4.63B $3.72B $3.25B $2.37B $2.07B $1.73B $1.31B $993M $818M $365M $475M $243M
Shares Outstanding 12-point trend, +30.9% 100,100,000 99,400,000 98,700,000 96,500,000 94,900,000 93,500,000 92,300,000 90,797,000 88,793,903 86,883,300 86,262,594 76,465,942
现金流 15
NBIX 的年度现金流数据
指标 趋势 202520242023202220212020201920182017201620152014
D&A 5-point trend, +386.6% · · · · · · · $4M $2M $1M $1M $827.0K
Stock-based Comp 12-point trend, +1998.8% $218M $196M $194M $173M $134M $100M $75M $58M $43M $28M $28M $10M
Deferred Tax 8-point trend, +164200000.00 $164M $-123M $-61M $22M $6M $-311M $0 $0 · · · ·
Amort. of Intangibles 6-point trend, +4100000.00 $4M $4M $4M $500.0K $0 $0 · · · · · ·
Operating Cash Flow 12-point trend, +1760.4% $783M $595M $390M $339M $256M $228M $147M $101M $-94M $-106M $-38M $-47M
CapEx 12-point trend, +2009.2% $34M $38M $28M $16M $23M $11M $15M $25M $7M $4M $2M $2M
Investing Cash Flow 10-point trend, -334.1% $-264M $-127M $-467M $-177M $-130M $4M $-211M $-243M $-251M $113M · ·
Stock Issued 12-point trend, -6.7% $129M $122M $65M $45M $28M $29M $32M $30M $14M $2M $277M $139M
Stock Repurchased 4-point trend, +167700000.00 $168M $300M $0 $0 · · · · · · · ·
Net Stock Activity 11-point trend, -127.6% $-38M $-178M $65M $45M $28M $29M $27M $30M $14M $2M · $139M
Financing Cash Flow 10-point trend, -1702.5% $-38M $-487M $65M $-234M $27M $-158M $32M $30M $517M $2M · ·
Net Change in Cash 12-point trend, +3584.6% $480M $-18M $-12M $-73M $154M $75M $-32M $-112M $171M $9M $43M $-14M
Taxes Paid $81M · · · · · · · · · · ·
Free Cash Flow 11-point trend, +1635.7% $749M $557M $362M $323M $233M $218M $137M $77M $-101M $-110M · $-49M
Levered FCF 6-point trend, +661.3% · · $358M $318M $210M $92M $112M $47M · · · ·
盈利能力 7
NBIX 的年度盈利能力数据
指标 趋势 202520242023202220212020201920182017201620152014
Operating Margin 10-point trend, +102.2% 21.6% 24.2% 13.3% 16.7% 9.0% 15.6% 9.2% 8.2% -81.3% -982.5% · ·
Net Margin 10-point trend, +101.8% 16.7% 14.5% 13.2% 10.4% 7.9% 38.9% 4.7% 4.7% -88.2% -940.6% · ·
Pretax Margin 8-point trend, +409.5% 24.7% 20.6% 17.6% 14.4% 8.9% 10.2% 5.9% 4.8% · · · ·
EBITDA Margin 10-point trend, +102.2% 21.6% 24.2% 13.3% 16.7% 9.0% 15.6% 9.2% 8.2% -81.3% -982.5% · ·
ROA 11-point trend, +137.6% 11.5% 9.8% 8.9% 7.0% 4.7% 26.8% 3.2% 2.3% -24.1% -33.6% · -30.4%
ROE 11-point trend, +143.7% 16.1% 12.9% 11.8% 9.5% 6.6% 42.2% 6.1% 4.5% -41.5% -38.2% · -36.8%
ROIC 8-point trend, +74.0% 12.9% 15.5% 8.5% 10.5% 6.6% 55.2% 9.0% 7.4% · · · ·
流动性与偿付能力 3
NBIX 的年度流动性与偿付能力数据
指标 趋势 202520242023202220212020201920182017201620152014
Current Ratio 11-point trend, -73.2% 3.4 3.4 2.5 2.7 4.0 5.4 1.5 8.4 10.2 10.2 · 12.7
Quick Ratio 11-point trend, -84.8% 1.9 1.4 1.1 1.1 3.6 5.1 1.4 2.2 10.1 10.1 · 12.4
Interest Coverage 7-point trend, +910.6% · · 54.5 35.1 4.0 5.0 2.3 1.2 -6.7 · · ·
效率 3
NBIX 的年度效率数据
指标 趋势 202520242023202220212020201920182017201620152014
Asset Turnover 11-point trend, +0.69 0.7 0.7 0.7 0.7 0.6 0.7 0.7 0.5 0.3 0.0 · 0.0
Inventory Turnover 5-point trend, +0.2% 0.8 0.7 1.1 0.7 · · · 0.8 · · · ·
Receivables Turnover 9-point trend, -52.7% 4.9 5.1 4.8 5.6 6.6 7.4 8.6 10.3 10.4 · · ·
每股 5
NBIX 的年度每股数据
指标 趋势 202520242023202220212020201920182017201620152014
Book Value / Share 11-point trend, +1090.7% $32.50 $26.05 $22.61 $17.70 $14.48 $12.04 $6.90 $5.29 $4.19 $3.62 · $2.73
Revenue / Share 11-point trend, +27.91 $27.91 $22.71 $18.68 $15.05 $11.58 $10.69 $8.23 $4.73 $1.83 $0.17 · $0.00
Cash Flow / Share 11-point trend, +1308.1% $7.64 $5.74 $3.86 $3.43 $2.62 $2.34 $1.59 $1.06 $-1.07 $-1.22 · $-0.63
Cash / Share 11-point trend, +1656.1% $7.12 $2.34 $2.54 $2.72 $3.59 $2.00 $1.22 $1.56 $2.87 $0.96 · $0.41
EPS (TTM) 12-point trend, +676.5% $4.67 $3.29 $2.47 $1.56 $0.92 $4.16 $0.39 $0.22 $-1.62 $-1.63 $-1.05 $-0.81
增长率 9
NBIX 的年度增长率数据
指标 趋势 202520242023202220212020201920182017201620152014
Revenue YoY 5-point trend, +156.0% 21.4% 24.8% 26.8% 31.3% 8.4% · · · · · · ·
Revenue CAGR 3Y 3-point trend, +11.9% 24.3% 27.6% 21.7% · · · · · · · · ·
Revenue CAGR 5Y 22.3% · · · · · · · · · · ·
EPS YoY 5-point trend, +153.9% 41.9% 33.2% 58.3% 69.6% -77.9% · · · · · · ·
EPS CAGR 3Y 3-point trend, +376.6% 44.1% 52.9% -16.0% · · · · · · · · ·
EPS CAGR 5Y 2.3% · · · · · · · · · · ·
Net Income YoY 5-point trend, +151.6% 40.2% 36.7% 61.6% 72.4% -78.0% · · · · · · ·
Net Income CAGR 3Y 3-point trend, +404.1% 45.8% 56.2% -15.0% · · · · · · · · ·
Net Income CAGR 5Y 3.3% · · · · · · · · · · ·
估值 (TTM) 10
NBIX 的年度估值 (TTM)数据
指标 趋势 202520242023202220212020201920182017201620152014
Revenue TTM 12-point trend, +2860500000.00 $2.86B $2.36B $1.89B $1.49B $1.13B $1.05B $788M $451M $162M $15M $20M $0
Net Income TTM 12-point trend, +890.5% $479M $341M $250M $154M $90M $407M $37M $21M $-143M $-141M $-89M $-61M
Market Cap 11-point trend, +731.1% $14.20B $13.57B $13.00B $11.53B $8.08B $8.96B $9.92B $6.48B $6.89B $3.36B · $1.71B
P/E 12-point trend, +210.1% 30.4 41.5 53.3 76.6 92.6 23.0 275.6 324.6 -47.9 -23.7 -53.9 -27.6
P/S 10-point trend, -97.8% 5.0 5.8 6.9 7.7 7.1 8.6 12.6 14.4 42.6 224.2 · ·
P/B 11-point trend, -46.7% 4.4 5.2 5.8 6.7 5.9 8.0 15.6 13.5 18.5 10.7 · 8.2
P / Tangible Book 6-point trend, -45.2% 4.4 5.3 5.9 6.9 5.9 8.0 · · · · · ·
P / Cash Flow 11-point trend, +150.1% 18.1 22.8 33.4 34.0 31.5 39.2 65.2 64.0 -73.0 -31.7 · -36.2
P / FCF 11-point trend, +154.1% 19.0 24.4 36.0 35.7 34.7 41.2 72.2 84.7 -68.0 -30.5 · -35.0
Earnings Yield 12-point trend, +190.6% 3.3% 2.4% 1.9% 1.3% 1.1% 4.3% 0.36% 0.31% -2.1% -4.2% -1.9% -3.6%

财务报表 损益表、资产负债表、现金流量表 — 年度，近5年

损益表
2025-12-312024-12-312023-12-312022-12-312021-12-31
收入 $2.86B$2.36B$1.89B$1.49B$1.13B
营业利润率 % 21.6%24.2%13.3%16.7%9.0%
净收入 $479M$341M$250M$154M$90M
稀释后每股收益 (EPS) $4.67$3.29$2.47$1.56$0.92
资产负债表
2025-12-312024-12-312023-12-312022-12-312021-12-31
流动比率 3.43.42.52.74.0
速动比率 1.91.41.11.13.6
现金流
2025-12-312024-12-312023-12-312022-12-312021-12-31
自由现金流 $749M$557M$362M$323M$233M

最新新闻 提及该公司的近期头条新闻

交易信号 近期买入/卖出信号，包含入场价和风险/回报比

我的指标 您的个人关注列表 — 来自完整基本面的选定行

📊

选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。

您的选择已保存，并会跟随您浏览所有股票。

机构持有人 (13F) 827 家申报者 · $10.1B 总计 · 截至 2026年6月30日

在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。

机构活动 — Q2 2026 与上一季度对比
新仓位 已退出持仓 增加 减少 净股数变动
153 (+57 与上一季度对比) 62 (-36 与上一季度对比) 301 (+9 与上一季度对比) 223 (+8 与上一季度对比) -638K

与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。

机构 价值 股份 % 已追踪的13F 类型
Dodge & Cox $941218594 5584707 9.32% 股份
VANGUARD PORTFOLIO MANAGEMENT LLC $838307078 4974083 8.30% 股份
VANGUARD CAPITAL MANAGEMENT LLC $766048708 4545339 7.58% 股份
STATE STREET CORP $739126759 4385598 7.32% 股份
RENAISSANCE TECHNOLOGIES LLC $393680402 2335897 3.90% 股份
TWO SIGMA INVESTMENTS, LP $349922479 2076260 3.46% 股份
Vestal Point Capital, LP $316845800 1880000 3.14% 股份
GEODE CAPITAL MANAGEMENT, LLC $294151210 1750392 2.91% 股份
RTW INVESTMENTS, LP $213689740 1267925 2.12% 股份
NORGES BANK $164132866 973880 1.62% 股份
FIRST TRUST ADVISORS LP $155578851 923125 1.54% 股份
JACOBS LEVY EQUITY MANAGEMENT, INC $122375286 726112 1.21% 股份
TWO SIGMA ADVISERS, LP $119504823 842592 1.18% 股份
Swedbank AB $109730107 651082 1.09% 股份
VANGUARD FIDUCIARY TRUST CO $109170737 647763 1.08% 股份
DIMENSIONAL FUND ADVISORS LP $109070816 647171 1.08% 股份
VICTORY CAPITAL MANAGEMENT INC $104238729 618499 1.03% 股份
Caisse de depot et placement du Quebec $91002327 539961 0.90% 股份
ARMISTICE CAPITAL, LLC $90307457 535838 0.89% 股份
PRIMECAP MANAGEMENT CO/CA/ $82807988 491340 0.82% 股份
AMERIPRISE FINANCIAL INC $79666260 472708 0.79% 股份
Hood River Capital Management LLC $79082184 469233 0.78% 股份
ROYAL BANK OF CANADA $73348000 435207 0.73% 股份
Pictet Asset Management Holding SA $72751030 430635 0.72% 股份
Gotham Asset Management, LLC $62622213 371568 0.62% 股份
Fiera Capital Corp $61558083 365254 0.61% 股份
BlackRock, Inc. $61129161 362709 0.61% 股份
ALLIANCEBERNSTEIN L.P. $60767710 461270 0.60% 股份
Vinva Investment Management Ltd $58838530 346109 0.58% 股份
AustralianSuper Pty Ltd $58817535 348993 0.58% 股份
GOLDMAN SACHS GROUP INC $58206259 345366 0.58% 股份
BRAIDWELL LP $56656579 336171 0.56% 股份
RHUMBLINE ADVISERS $52723054 312832 0.52% 股份
Clearbridge Investments, LLC $47391031 281194 0.47% 股份
SEIZERT CAPITAL PARTNERS, LLC $46740991 277337 0.46% 股份
Swiss National Bank $45319062 268900 0.45% 股份
BARCLAYS PLC $44228304 262428 0.44% 股份
ENVESTNET ASSET MANAGEMENT INC $44187600 262192 0.44% 股份
WORLDQUANT MILLENNIUM ADVISORS LLC $44038027 261299 0.44% 股份
Candriam S.C.A. $43932854 260926 0.43% 股份
BNP PARIBAS FINANCIAL MARKETS $43921064 260605 0.43% 股份
FMR LLC $40551501 240612 0.40% 股份
PRINCIPAL FINANCIAL GROUP INC $40285595 239034 0.40% 股份
California Public Employees Retirement System $39090345 231942 0.39% 股份
RENAISSANCE GROUP LLC $38589515 228970 0.38% 股份
Assenagon Asset Management S.A. $37516902 222606 0.37% 股份
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. $37508000 222554 0.37% 股份
Sumitomo Mitsui Trust Group, Inc. $36317270 215488 0.36% 股份
Carmignac Gestion $36083344 214100 0.36% 股份
PFM Health Sciences, LP $35966549 213407 0.36% 股份
Bridgewater Associates, LP $34663773 205677 0.34% 股份
LOS ANGELES CAPITAL MANAGEMENT LLC $34304966 203548 0.34% 股份
Nantahala Capital Management, LLC $33707000 200000 0.33% 买入期权
BANK OF AMERICA CORP /DE/ $32143164 190721 0.32% 股份
MORGAN STANLEY $32058612 190219 0.32% 股份
SUSQUEHANNA INTERNATIONAL GROUP, LLP $31213608 185200 0.31% 卖出期权
FULLER & THALER ASSET MANAGEMENT, INC. $30192001 179149 0.30% 股份
PRUDENTIAL FINANCIAL INC $29909064 177465 0.30% 股份
SEB Asset Management AB $29789208 176754 0.29% 股份
Ensign Peak Advisors, Inc $29653059 175946 0.29% 股份
IEQ CAPITAL, LLC $29628432 175800 0.29% 股份
MACKENZIE FINANCIAL CORP $29609071 175685 0.29% 股份
NEW YORK STATE COMMON RETIREMENT FUND $29573511 175474 0.29% 股份
Korea Investment CORP $29154701 172989 0.29% 股份
PKO BP BANKOWY Universal Pension Society JSC $28786115 170802 0.28% 股份
Zurich Insurance Group Ltd/FI $28618254 169806 0.28% 股份
Impax Asset Management Group plc $26965600 160000 0.27% 股份
Nearwater Capital Markets, Ltd $26122925 155000 0.26% 股份
Mariner, LLC $25627342 152055 0.25% 股份
Integral Health Asset Management, LLC $25281000 150000 0.25% 股份
Rock Springs Capital Management LP $24395441 144750 0.24% 股份
Zurcher Kantonalbank (Zurich Cantonalbank) $23738829 140854 0.24% 股份
Fisher Asset Management, LLC $22769751 135104 0.23% 股份
Aware Super Pty Ltd as trustee of Aware Super $22056175 130870 0.22% 股份
RAYMOND JAMES FINANCIAL INC $22009323 130592 0.22% 股份
Hudson Bay Capital Management LP $21909550 130000 0.22% 股份
Life Cycle Investment Partners Ltd $21287319 126308 0.21% 股份
VIRGINIA RETIREMENT SYSTEMS ET Al $20937370 147623 0.21% 股份
DNB Asset Management AS $20280996 120337 0.20% 股份
JANE STREET GROUP, LLC $20072518 119100 0.20% 卖出期权
Sarissa Capital Management LP $19639889 116533 0.19% 股份
Andra AP-fonden $19522682 148191 0.19% 股份
AMERICAN CENTURY COMPANIES INC $19061140 113099 0.19% 股份
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main $18885863 112059 0.19% 股份
Man Group plc $18859404 111902 0.19% 股份
Mitsubishi UFJ Asset Management Co., Ltd. $18788956 111484 0.19% 股份
UBS Group AG $18243577 108248 0.18% 股份
Robeco Institutional Asset Management B.V. $18197736 107976 0.18% 股份
LOOMIS SAYLES & CO L P $18108412 107446 0.18% 股份
Retirement Systems of Alabama $17527134 103997 0.17% 股份
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM $17474389 132643 0.17% 股份
ING GROEP NV $17224277 102200 0.17% 股份
Legal & General Group Plc $17176748 101918 0.17% 股份
RICE HALL JAMES & ASSOCIATES, LLC $16886364 100195 0.17% 股份
Universal- Beteiligungs- und Servicegesellschaft mbH $16827572 99912 0.17% 股份
CWM, LLC $16696728 126740 0.17% 股份
CAPITAL FUND MANAGEMENT S.A. $16536148 98117 0.16% 股份
Clark Capital Management Group, Inc. $15629612 92738 0.15% 股份
Distillate Capital Partners LLC $15604993 92592 0.15% 股份
LAZARD ASSET MANAGEMENT LLC $15399211 91371 0.15% 股份

公司内部人士 42 位内幕人士 · 21 位高管 · 15 位董事

内部人士 角色 上次活动 持股数量 买入 12个月 卖出 12个月 净额 12个月
Kyle Gano Chief Executive Officer 2025年2月13日 M 139907 0 0 $0
Matt Abernethy Chief Financial Officer 2025年2月13日 M 35810 0 0 $0
Timothy Coughlin Chief Financial Officer 2017年2月6日 S 137961 0 0 $0
David-Alexandre C Gros President & COO 2017年2月6日 A — 0 0 $0
Ingrid Delaet Chief Regulatory Officer 2026年7月10日 M 16225 0 5 $-3747962
Darin Lippoldt Chief Legal Officer 2026年7月9日 M 54729 0 4 $-3497443
Sanjay Chandru Keswani Chief Medical Officer 2026年6月2日 F 1479 0 0 $0
Julie Cooke Chief Human Resources Officer 2026年6月2日 M 22374 0 1 $-2200685
David W. Boyer Chief Corp. Affairs Officer 2025年2月13日 M 3565 0 0 $0
Eiry Roberts Chief Medical Officer 2025年2月13日 M 35640 0 0 $0
Eric Benevich Chief Commercial Officer 2025年2月13日 M 44689 0 0 $0
Malcolm Lloyd-Smith Chief Integration Officer 2023年2月8日 S 42337 0 0 $0
Dimitri E. Grigoriadis Chief Research Officer 2022年1月31日 A 82273 0 0 $0
Haig P. Bozigian Chief Development Officer 2021年2月8日 A 157651 0 0 $0
Christopher Flint Obrien Former Chief Medical Officer 2018年2月5日 A 55946 0 0 $0
VALEUR JENSEN MARGARET E EVP and General Counsel 2011年8月31日 A 118256 0 0 $0
Richard J Ranieri Sr. VP, Human Resources 2008年2月27日 A 9667 0 0 $0
Wendall Wierenga EVP, Research & Development 2006年1月19日 A 5023 0 0 $0
Henry Pan Executive VP and CMO 2005年6月3日 A 11216 0 0 $0
Robert J Little SVP, Commercial Operations 2005年2月18日 A — 0 0 $0
SAUNDERS JOHN Vice President Research (Chem) 2003年12月18日 S 7966 0 0 $0
Leslie V Norwalk 董事 2026年7月29日 M 2430 0 2 $-437584
SHERWIN STEPHEN A 董事 2026年6月5日 M 15860 0 5 $-4132990
William H Rastetter 董事 2026年5月27日 A 43678 0 1 $-2732760
Kevin Charles Gorman 董事 2026年5月27日 A 511293 0 1 $-37824431
Christine A Poon 董事 2026年5月27日 A 4753 0 0 $0
POPS RICHARD F 董事 2026年5月27日 A 37798 0 1 $-2364750
LYONS GARY A 董事 2026年5月27日 A 122141 0 1 $-2289150
MORROW GEORGE J 董事 2026年5月27日 A 10386 0 1 $-2150550
Johanna Mercier 董事 2025年5月22日 M 3535 0 0 $0
Alfred Sandrock 董事 2019年5月22日 A — 0 0 $0
Corinne H Nevinny 董事 2018年5月24日 A 43283 0 0 $0
Thomas W Mitchell 董事 2015年5月28日 A 1000 0 0 $0
VALE WYLIE W 董事 2011年5月25日 A 231372 0 0 $0
Adrian Adams 董事 2006年6月30日 A — 0 0 $0
NEUROCRINE BIOSCIENCES INC 10% 所有者 2023年2月23日 P 8575316 0 0 $0
Jude Onyia — 2026年8月4日 G 20996 0 1 $-1762710
Shalini Sharp — 2026年5月27日 A 4088 0 0 $0
MOLLICA JOSEPH A — 2017年5月22日 A 56042 0 0 $0
HAWRAN PAUL W — 2006年9月18日 J 132000 0 0 $0
Lawrence Steinman — 2005年3月2日 S 15500 0 0 $0
CONLON PAUL J — 2003年12月16日 S 57335 0 0 $0

来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖

激进投资者及 5%+ 股东 1 持仓

提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。

申报人 已申报 持股 状态 目的 申报
Neurocrine Biosciences, Inc. ×3 申报 2023年2月24日 — 初始申报 — SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

ETF持仓 由 129 只交易所交易基金持有

权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。

基金 权重 单位 截至 来源
MCOW · Pacer Funds Trust 2.17% 162 NS 2026年4月30日 N-PORT
FGSI · First Trust Exchange-Traded Fund IV 2.01% 457 NS 2026年4月30日 N-PORT
SMRI · EA Series Trust 1.95% 79947 NS 2026年4月30日 N-PORT
BUL · Pacer Funds Trust 1.66% 16032 NS 2026年4月30日 N-PORT
BBP · ETFis Series Trust I 1.38% 6192 NS 2026年4月30日 N-PORT
ILDR · First Trust Exchange-Traded Fund ... 1.29% 23318 NS 2026年5月31日 N-PORT
AGNG · Global X Funds 1.12% 5792 NS 2026年5月31日 N-PORT
LABU · Direxion Shares ETF Trust 0.95% 37476 NS 2026年4月30日 N-PORT
AGRW · ALLSPRING EXCHANGE-TRADED FUNDS T... 0.93% 7516 NS 2026年4月30日 N-PORT
FXH · First Trust Exchange-Traded Alpha... 0.87% 57454 NS 2026年4月30日 N-PORT
COWG · Pacer Funds Trust 0.81% 132963 NS 2026年4月30日 N-PORT
BIB · ProShares Trust 0.80% 3712 NS 2026年5月31日 N-PORT
TMFX · RBB Fund, Inc. 0.76% 1542 NS 2026年5月31日 N-PORT
ABOT · Abacus FCF ETF Trust 0.72% 240 NS 2026年4月30日 N-PORT
CLSE · Trust for Professional Managers 0.66% 25529 NS 2026年5月31日 N-PORT
MIDE · DBX ETF Trust 0.64% 136 NS 2026年5月29日 N-PORT
JDOC · J.P. Morgan Exchange-Traded Fund ... 0.63% 533 NS 2026年4月30日 N-PORT
IQSM · New York Life Investments ETF Trust 0.55% 13166 NS 2026年4月30日 N-PORT
SMDX · Tidal Trust III 0.55% 5215 NS 2026年4月30日 N-PORT
QLV · FlexShares Trust 0.46% 5915 NS 2026年4月30日 N-PORT
FNY · First Trust Exchange-Traded Alpha... 0.40% 15614 NS 2026年4月30日 N-PORT
PTMC · Pacer Funds Trust 0.39% 11519 NS 2026年4月30日 N-PORT
MVV · ProShares Trust 0.34% 3468 NS 2026年5月31日 N-PORT
SXQG · EXCHANGE TRADED CONCEPTS TRUST 0.34% 1461 NS 2026年5月31日 N-PORT
BKMC · BNY Mellon ETF Trust 0.34% 16076 NS 2026年4月30日 N-PORT
SCHM · SCHWAB STRATEGIC TRUST 0.29% 271303 NS 2026年5月31日 N-PORT
MIDU · Direxion Shares ETF Trust 0.26% 1662 NS 2026年4月30日 N-PORT
BBMC · J.P. Morgan Exchange-Traded Fund ... 0.26% 40014 NS 2026年4月30日 N-PORT
FSMD · FIDELITY COVINGTON TRUST 0.25% 44691 NS 2026年4月30日 N-PORT
UMDD · ProShares Trust 0.24% 484 NS 2026年5月31日 N-PORT
JPME · J.P. Morgan Exchange-Traded Fund ... 0.23% 7607 NS 2026年4月30日 N-PORT
FHLC · FIDELITY COVINGTON TRUST 0.21% 45968 NS 2026年4月30日 N-PORT
AVMC · AMERICAN CENTURY ETF TRUST 0.18% 4529 NS 2026年5月31日 N-PORT
AVIE · AMERICAN CENTURY ETF TRUST 0.17% 108 NS 2026年5月31日 N-PORT
FNDA · SCHWAB STRATEGIC TRUST 0.16% 89904 NS 2026年5月31日 N-PORT
FNX · First Trust Exchange-Traded Alpha... 0.14% 13779 NS 2026年4月30日 N-PORT
DEUS · DBX ETF Trust 0.12% 2125 NS 2026年5月29日 N-PORT
FAD · First Trust Exchange-Traded Alpha... 0.12% 4295 NS 2026年4月30日 N-PORT
AFMC · First Trust Exchange-Traded Fund ... 0.09% 906 NS 2026年5月31日 N-PORT
HEQQ · J.P. Morgan Exchange-Traded Fund ... 0.09% 209 NS 2026年4月30日 N-PORT
MSSM · MORGAN STANLEY PATHWAY FUNDS 0.08% 3864 NS 2026年5月31日 N-PORT
LRND · New York Life Investments ETF Trust 0.08% 1694 NS 2026年4月30日 N-PORT
HELO · J.P. Morgan Exchange-Traded Fund ... 0.07% 20990 NS 2026年4月30日 N-PORT
DFUV · Dimensional ETF Trust 0.06% 70547 NS 2026年4月30日 N-PORT
SCHG · SCHWAB STRATEGIC TRUST 0.06% 212211 NS 2026年5月31日 N-PORT
GGUS · Goldman Sachs ETF Trust 0.05% 1464 NS 2026年5月31日 N-PORT
NBCR · Neuberger Berman ETF Trust 0.05% 2533 NS 2026年5月31日 N-PORT
DFAC · Dimensional ETF Trust 0.04% 135667 NS 2026年4月30日 N-PORT
AVSU · AMERICAN CENTURY ETF TRUST 0.03% 976 NS 2026年5月31日 N-PORT
ONEQ · Fidelity Commonwealth Trust 0.03% 22757 NS 2026年5月31日 N-PORT